Evidence map›Paper›PMID 42683315›Full record

ReviewFrontiers in molecular neuroscience2026

The ERK MAPK pathway in mesenchymal glioblastoma: tumorigenesis, microenvironmental reprogramming, and the therapeutic promise of RAS(ON) multi-selective inhibition.

Uma M Basole, Mary M Fitzpatric, Joseph Donohoe, Shashank Obulasetti, William Snider, Emily Haugen, Damir Garcia, Ana Gonzalez-Manteiga, Mathieu Sertorio, Marc Oria

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in molecular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Uma M BasoleDepartment of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Mary M FitzpatricDepartment of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Joseph DonohoeDepartment of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Shashank ObulasettiDepartment of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
William SniderDepartment of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Emily HaugenDepartment of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Damir GarciaDepartment of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Ana Gonzalez-ManteigaDepartment of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Mathieu Sertorio *Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Marc Oria *Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) remains one of the most lethal malignancies in adults, with a median survival of 15 months under the current standard of care. The lack of effective targeted therapies is a critical gap, particularly for the mesenchymal subtype of glioblastoma (MES-GBM), which accounts for up to 49% of GBM cases and carries the worst prognosis. Although direct RAS mutations are rare in GBM, mutations in upstream ERK MAPK pathway regulators such as loss-of-function of neurofibromin 1 (

Indexed as

daraxonrasibERK-MAPK signalingglioblastomamesenchymal glioblastomaNF1RAS(ON) inhibitorstargeted therapytumor microenvironment

Identifiers

PMID42683315
PMCPMC13531517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.